NCT06471361 2026-03-27
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
Clinical Trials
41 trialsNCT04818671 2026-01-22
ADAPTSC+
argenx
Phase 3 Completed
NCT06764160 2026-01-15
ECU-MG-304
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT03971422 2025-12-24
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
NCT05451212 2025-11-10
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis
Cabaletta Bio
Phase 1 Completed
NCT05681715 2025-11-06
A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
UCB Pharma
Phase 3 Completed
NCT04980495 2025-11-05
ADAPT NXT
argenx
Phase 3 Completed
NCT05514873 2025-09-03
An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
UCB Pharma
Phase 3 Completed
NCT04115293 2025-07-16
RAISE
UCB Pharma
Phase 3 Completed
NCT05737160 2025-05-23
Study of Telitacicept in Generalized Myasthenia Gravis
RemeGen Co., Ltd.
Phase 3 Completed
NCT04650854 2025-04-18
A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
NCT06381284 2025-03-25
Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment
ZS Associates
Completed
NCT03759366 2024-12-11
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT02965573 2024-08-28
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
argenx
Phase 2 Completed
NCT04176211 2024-06-03
The Impact of Myasthenia Gravis in the Real World
Vitaccess Ltd
Completed
NCT03920293 2024-05-28
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT03304054 2024-03-12
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
Catalyst Pharmaceuticals, Inc.
Phase 3 Completed
NCT06256172 2024-02-13
Medlink
Olawuyi Racett Nigeria Ltd
Phase NA Completed
NCT03863080 2023-12-20
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
Immunovant Sciences GmbH
Phase 2 Completed
NCT04124965 2023-09-05
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
NCT03770403 2023-07-14
ADAPT+
argenx
Phase 3 Completed
NCT03772587 2023-06-27
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
Momenta Pharmaceuticals, Inc.
Phase 2 Completed
NCT04159805 2023-06-02
A Study of TAK-079 in People With Generalized Myasthenia Gravis
Takeda
Phase 2 Completed
NCT04346888 2023-03-08
A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients
Harbour BioMed (Guangzhou) Co. Ltd.
Phase 2 Completed
NCT05039190 2023-03-08
MG
Harbour BioMed (Guangzhou) Co. Ltd.
Phase 3 Completed
NCT04735432 2023-02-28
ADAPTsc
argenx
Phase 3 Completed
NCT03315130 2022-07-27
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
UCB Pharma
Phase 2 Completed
NCT03669588 2022-02-08
ADAPT
argenx
Phase 3 Completed
NCT03052751 2021-08-03
Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
UCB Pharma
Phase 2 Completed
NCT04590716 2021-07-29
Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
doc.ai inc
Completed
NCT02565576 2021-01-05
Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis
Novartis
Phase 2 Completed
NCT02473965 2020-03-30
Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
Grifols Therapeutics LLC
Phase 2 Completed
NCT02301624 2020-02-05
Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT01997229 2019-07-16
Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT02473952 2019-03-05
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
Grifols Therapeutics LLC
Phase 2 Completed
NCT02609022 2019-01-28
Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis
CuraVac
Phase 1/2 Completed
NCT01325571 2016-03-09
A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis
Astellas Pharma Inc
Phase 3 Completed
NCT00309088 2014-08-25
FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients
Astellas Pharma Inc
Phase 3 Completed
NCT00515450 2010-07-30
Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis
Benesis Corporation
Phase 3 Completed
NCT00309101 2009-06-03
An Open Study for Steroid Resistant, Non-Thymectomized MG Patients
Astellas Pharma Inc
Phase 3 Completed
NCT00683969 2008-05-26
A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis
Hoffmann-La Roche
Phase 3 Completed